The short answer: Not much right away, although failing to pay creditors is never a good thing for a nation's creditworthiness
Coca-Cola’s North America president, Sandy Douglas, oversees a relaunch of America’s No. 1 soft drink
Four years after the Citizens United decision, out-of-state cash is flowing down to state races
Phony phone-bill items from third-party scammers date back almost 20 years
Yves Béhar's Public Office Landscape turns the workstation into a social hub
A Bluetooth-enabled sneaker from an India-based startup doubles as a fitness tracker and personal tour guide
After Virginia Tech and Miami of Ohio shut down their regional full-time MBA programs, who’s next?
Critics say the agency charged with keeping regulations from burdening small companies actually serves big corporate interests
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.